US7056916B2
(en)
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
DE102004019539A1
(en)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drugs for the treatment of respiratory diseases
|
EP2422786B1
(en)
|
2004-04-22 |
2014-08-13 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
New medicine combinations for treating respiratory diseases
|
EP1789394A1
(en)
*
|
2004-05-13 |
2007-05-30 |
Boehringer Ingelheim International Gmbh |
Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
|
US7220742B2
(en)
|
2004-05-14 |
2007-05-22 |
Boehringer Ingelheim International Gmbh |
Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
|
US20050256115A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Boehringer Ingelheim International Gmbh |
Aerosol formulation for the inhalation of beta-agonists
|
US7745621B2
(en)
|
2004-05-14 |
2010-06-29 |
Boehringer Ingelheim International Gmbh |
Long acting bronchodilators for the treatment of respiratory diseases
|
DE102004024452A1
(en)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Aerosol formulation for the inhalation of beta agonists
|
DE102004024451A1
(en)
*
|
2004-05-14 |
2005-12-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder formulations for inhalation containing enantiomerically pure beta agonists
|
DE102004024454A1
(en)
*
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
|
DE102004024453A1
(en)
*
|
2004-05-14 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New long-acting bronchodilators for the treatment of respiratory diseases
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
DE102004045648A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New betamimetics for the treatment of respiratory diseases
|
GT200500281A
(en)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
ORGANIC COMPOUNDS.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
DE102005007654A1
(en)
|
2005-02-19 |
2006-08-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New long-acting betamimetics for the treatment of respiratory diseases
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DE102005030733A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
RU2442771C2
(en)
|
2005-08-08 |
2012-02-20 |
Арджента Дискавери Лтд |
Derivants of bicyclo[2, 2, 1] hept-7-ylamine and their applications
|
PL1917253T3
(en)
*
|
2005-08-15 |
2015-06-30 |
Boehringer Ingelheim Int |
Method for producing betamimetics
|
US20070086957A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Thierry Bouyssou |
Combination of medicaments for the treatment of respiratory diseases
|
US20070088030A1
(en)
*
|
2005-10-10 |
2007-04-19 |
Barbara Niklaus-Humke |
Aerosol formulations for the inhalation of beta-agonists
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
WO2007054498A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Aerosolformulation for inhalation
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
EP1986644A1
(en)
*
|
2006-02-16 |
2008-11-05 |
Boehringer Ingelheim International GmbH |
Drug combinations for the treatment of respiratory tract diseases
|
PE20080142A1
(en)
|
2006-03-15 |
2008-04-14 |
Boehringer Ingelheim Int |
ENANTHOMERICALLY PURE BETA-AGONISTS AND THEIR PREPARATION PROCEDURES
|
KR20080110925A
(en)
|
2006-04-21 |
2008-12-19 |
노파르티스 아게 |
Purine derivatives for use as adenosin a2a receptor agonists
|
WO2008017638A1
(en)
*
|
2006-08-07 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
|
UY30542A1
(en)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS
|
UY30543A1
(en)
*
|
2006-08-18 |
2008-03-31 |
Boehringer Ingelheim Int |
AEROSOL FORMULATION FOR INHALATION OF BETA- AGONISTS
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
JP2010508315A
(en)
|
2006-10-30 |
2010-03-18 |
ノバルティス アーゲー |
Heterocyclic compounds as anti-inflammatory agents
|
EA016199B1
(en)
|
2007-01-10 |
2012-03-30 |
Айрм Ллк |
Compounds and compositions as channel activating protease inhibitors
|
US20100022770A1
(en)
*
|
2007-01-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Process for the manufacturing of beta mimetics
|
US8318935B2
(en)
|
2007-05-07 |
2012-11-27 |
Novartis Ag |
Organic compounds 75074
|
JP5455922B2
(en)
|
2007-12-10 |
2014-03-26 |
ノバルティス アーゲー |
Organic compounds
|
ES2442930T3
(en)
|
2008-01-11 |
2014-02-14 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
WO2009150137A2
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
SI2379507T1
(en)
|
2008-12-30 |
2014-02-28 |
Pulmagen Therapeutics (Inflammation) Limited |
Sulfonamide compounds for the treatment of respiratory disorders
|
DK2391366T3
(en)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
JP5819831B2
(en)
|
2009-08-17 |
2015-11-24 |
インテリカイン, エルエルシー |
Heterocyclic compounds and their use
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
ES2886022T3
(en)
*
|
2010-09-21 |
2021-12-16 |
Intekrin Therapeutics Inc |
Solid antidiabetic pharmaceutical compositions
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
BR112013021638A2
(en)
|
2011-02-25 |
2016-08-02 |
Irm Llc |
"trk inhibiting compounds, their use and compositions comprising them"
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
US20130209543A1
(en)
|
2011-11-23 |
2013-08-15 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CA2868202C
(en)
|
2012-04-03 |
2021-08-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
EP2906218B1
(en)
|
2012-10-09 |
2016-12-14 |
Boehringer Ingelheim International GmbH |
Beta-2-adrenoceptor agonist for the treatment of cough
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
AU2014391610B2
(en)
|
2014-04-24 |
2018-01-25 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
BR112016024533A8
(en)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
amino pyrazine derivatives as phosphatidylinositol 3-kinase or salt inhibitors, their use, and pharmaceutical composition and combination
|
PT3134396T
(en)
|
2014-04-24 |
2019-12-16 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
JP2019536812A
(en)
|
2016-12-12 |
2019-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Nintedanib for use in methods of treating interstitial lung disease by co-administration with olodaterol
|
ES2900283T3
(en)
|
2016-12-20 |
2022-03-16 |
Inke Sa |
Improved process for the manufacture of (R)-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3 hydrochloride (4H)-one
|
CN108997248B
(en)
*
|
2018-08-06 |
2023-08-01 |
上海方予健康医药科技有限公司 |
Crystal form B of ondarot hydrochloride and preparation method thereof
|
CN109096218B
(en)
*
|
2018-08-06 |
2020-10-27 |
上海方予健康医药科技有限公司 |
Oxydterol hydrochloride crystal form A and preparation method thereof
|
AU2020290094B2
(en)
|
2019-06-10 |
2024-01-18 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
|
US20220306617A1
(en)
|
2019-08-28 |
2022-09-29 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
WO2021252577A1
(en)
*
|
2020-06-09 |
2021-12-16 |
Anovent Pharmaceutical (U.S.), Llc |
Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
|
US11331322B1
(en)
|
2021-09-15 |
2022-05-17 |
Santen Pharmaceutical Co., Ltd. |
Medicament for preventing and/or treating dry eye
|